Tag
The randomized CAVE-2 GOIM trial demonstrates that while adding avelumab to cetuximab rechallenge does not improve survival in metastatic colorectal cancer, liquid biopsy-based genomic hyper-selection identifies a subgroup of patients with
The PORTEC-4a trial confirms that molecular profiling safely guides adjuvant treatment in high-intermediate risk endometrial cancer, reducing overtreatment by 46% while maintaining non-inferiority in locoregional control compared to standar
The DYNAMIC-III trial validates circulating tumor DNA (ctDNA) as a strong prognostic marker in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with near-standard outcomes, but escalation
The randomized phase 2 ROME trial showed that genomically matched, MTB-guided therapy increased overall response rate and progression-free survival versus standard care in heavily pretreated advanced solid tumors, supporting a tumor-agnosti
A large international study reveals unique somatic mutation profiles and higher mutational burden in hypermutated early-onset colorectal cancer, highlighting the need for age-specific molecular diagnostics and management strategies.
